The PI3K inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjogren's syndrome
International Immunopharmacology（2021）
Key words
Parsaclisib,INCB050465,Phosphoinositide 3-kinase delta,Autoimmunity,Lupus,SjOgren's syndrome
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined